Glibenclamide Inhibits Cell Growth by Inducing G0/G1 Arrest in the Human Breast Cancer Cell Line MDA-MB-231

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

A sugar gel was claimed to trigger hair regrowth, but users reported no results and potential cancer risks. The discussion included comparisons to minoxidil and skepticism about the effectiveness of the sugar treatment.